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Department of Bioanalysis, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, BelgiumChronic obstructive pulmonary disease (COPD) is a common respi- underlying impaired lung function since thesewere involved in alterna-
ratory disease with progressive, incompletely reversible airflow limita-
tion [1]. Large differences in clinical presentation, response to therapy
and disease progression add to the complexity of this heterogeneous
lung disease. The abnormal inflammatory immune responses in the
lung of patients with COPD upon tobacco smoke exposure may be ge-
netically determined. The heritable risk for COPD has indeed been esti-
mated at 38% based on genome-wide single-nucleotide polymorphism
(SNP) data [2]. Beyond this specific nucleotide variation, the risk for
COPD could be in particular determined by epigenetic modifications
reflecting the alteration of gene activity and expression upon environ-
mental exposures such as tobacco smoke. Among the different epige-
netic mechanisms, methylation of DNA by adding a methyl group to
cytosine-phosphate-guanine (CpG) dinucleotide sequences in the
genome, has been studied most so far.
Epigenome wide association studies (EWAS) assessing a genome-
wide set of quantifiable modifications of DNA associated with respira-
tory function or disease, are rapidly emerging. They are promising in
increasing our understanding of the influence of smoke and early life
exposures into respiratory disease development [3,4]. For example, a re-
cent EWAS identified 59 differentially methylated regions (DMRs) in
cord blood associated with childhood lung function, of which 15% was
associated with COPD in adults [4]. The 330 genes associated with the
349 identified CpGs in a study among 1454 adults, highlighted path-
ways of inflammatory responses to stress and external stimuli [5].
Some annotated genes as PTPRN2 aremoreover able to differentiate be-
tween lung cancer, pulmonary fibrosis and COPD [6]. However, the het-
erogeneity in used methods, studied phenotypes and sampled tissues,
and the cross-sectional analyses at specific points in life have compli-
cated interpretation and replication of results so far [7,8].
The study of Bermingham et al. in EBioMedicine aimed to advance
the field of epigenetics in COPD by quantifying differentiallymethylated
sites in peripheral blood using the recently released 850 K Illumina EPIC
array in the Generation Scotland Scottish Family Health Study cohort
including 274 cases with COPD (GOLD2–4) and 2919 controls [9]. The
authors identified 28 differentially methylated sites of which 26 were
associated with lung function traits (mainly pre-bronchodilatory
FEV1), and two were associated with COPD. The identified annotated
genes may provide basic insight into the molecular mechanismsDOI of original article: https://doi.org/10.1016/j.ebiom.2019.03.072.
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half of the annotated genes have been previously linked to respiratory
function or disease. Only 7 CpGs (5 associated with FEV1 and 2 with
FEV1/FVC ratio) could be tested for replication due to the use of
the Illumina HumanMethylation450 BeadChip array with lower cover-
age in the Lothian Birth Cohort 1936. Two CpGs associated with
FEV1 (cg18181703 in SOCS3 and cg18608055 in SBNO2) and one asso-
ciated with FEV1/FVC ratio (cg03636183 in F2RL3) were replicated (p b
0.05/7) in this cohort of 895 elderly with spirometry data.
It is far too early to take these results towards current clinical prac-
tice or epigenetic drug development. First, confidence in these 28 epige-
netic associations would benefit from further replication and functional
investigation. Interestingly, two of the three replicated CpGs (i.e.
cg18181703 and cg18608055) improved theprediction of COPD risk be-
yond clinical variables in both cohorts. Not surprisingly, the other repli-
cated but non-discriminative CpG (i.e. cg03636183) was heavily
smoking dependent. The contribution of each CpG to the prediction
was rather marginal compared to the discriminative power of clinical
factors such as age, height or smoking. Nevertheless, evenwhen the im-
pact of each CpG on COPD risk is modest, the combined impact of mul-
tiple important CpGs into a epigenetic risk score might increase
potential for identifying high risk persons. A precedent here is put by
the successful genetic risk scores combining multiple SNP information
in predicting COPD [2].
Gene ontology and integrative analyses provided additional insight
into the biology potentially underlying these methylation associations
[9]. However, there are still technical limitationswith current functional
annotation approaches which use the proximity of the CpG to the
nearest gene for annotation and depend on the defined length of the
CpG and the human genome reference used. Still, many of the anno-
tated genes were linked to inflammatory and alternative splicing path-
ways and were coherent with findings from studies in lung tissue. The
latter is quite intriguing because differentially methylated sites were
identified usingperipheral blood samples [9]. Since altered gene expres-
sion upon environmental exposures such as tobacco smoke might be
cell and tissue specific, epigenetic changes might be different when
lung tissue samples would be explored. Still, COPD is characterized by
systematic manifestations and a subgroup of patients with COPD dem-
onstrate persistent low grade systemic inflammation [10].
In conclusion, this large EWAS provided several potentially interest-
ing differentially methylated sites related to impaired respiratory func-
tion. Integrative analysis exploring whether differential expression inC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
25L. Lahousse / EBioMedicine 43 (2019) 24–25lung tissue samples between COPD cases and controlswas related to the
genes correlated to the identified CpGs, confirmed pathways of axon
guidance, cytokine-cytokine receptor interactions and JAK-STAT signal-
ing. It remains a challenge whether respiratory impairment is caused
by, or reflected in the identified epigenetic changes related to these
annotated genes, but results like these raise the hope of everfinding epi-
genetic drugs to target respiratory impairment.
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